Categories Trading
7 days
30 days
All time
Recent
Popular
The proposal for $2000 stimulus checks is divisive, and not along simple left-right lines. Lots of disagreement among progressives, with people like Bernie Sanders very pro but many others not on board. Both sides have a point 1/
My take: the economics aren't very good, but the political economy may make such checks necessary 2/ https://t.co/XY7d9E8SDY
The key economic argument, which @crampell picks up on, is that given a slump that has affected people very unevenly, aid should concentrate on those actually suffering 3/
So if you have a fixed amount to spend, unemployment benefits and maybe small-business aid should be priorities, not checks that will in many cases go to people who are doing OK 4/
But is there a fixed amount to spend? No binding budget constraint for the feds, so this is all about politics. And my sense is that broad issuance of checks is actually kind of a loss leader, helping to sell a package that includes UI 5/
My take: the economics aren't very good, but the political economy may make such checks necessary 2/ https://t.co/XY7d9E8SDY
The key economic argument, which @crampell picks up on, is that given a slump that has affected people very unevenly, aid should concentrate on those actually suffering 3/
So if you have a fixed amount to spend, unemployment benefits and maybe small-business aid should be priorities, not checks that will in many cases go to people who are doing OK 4/
But is there a fixed amount to spend? No binding budget constraint for the feds, so this is all about politics. And my sense is that broad issuance of checks is actually kind of a loss leader, helping to sell a package that includes UI 5/
$ARPO Thread: Raz P2b glaucoma readout Dec 15 to Jan 15, assigning 90% POS, potential 3 to 5x, with (likely) partnership 1H21. Glaucoma dead for Big Pharma unless thereās a brand new MOA or pathway being targeted. Here we have bothā¦a new MOA (Tie2) and a new location (SC)
https://t.co/zsc2eBVI4e Tons of great preclinical work on TIE2 MOA showing clear correlation to SC integrity, adult-onset glaucoma, and disease-modifying effects. See mosaic if interested
What do KOL's think of the new MOA: Special session held at ARVO 2019 to discuss Tie2 for Glaucoma. $ARPO then completed a closely watched P1b with a topical formulation. Now, a P2b trial in 195 pts enrolled within 3 mos, a month ahead of schedule, in the middle of a pandemic.
SOC is PG (-7 mm Hg IOP) +/- adjunct (-1 to -1.5 mm delta). Best efficacy adjunct is Rocklatan (-1.5), but AE profile: hyperemia (60 vs 15%), pruritus (8 vs 2%) site pain (20 vs 7%) vs PG , + other AEās not seen with PG: 10% conjunctival hemorrhage, 15% verticillata. Almost DOA
But, sells $80 to $100M/yr US (same as $ARPO MC ha!). Every 0.3 mm reduction critical towards delaying vision loss. Rocklatan MOA was projected to make it a $1B drug, until AE profile (& payor delays) killed launch. $ARPO thesis: Raz efficacy >/= Rocklatan, without AE baggage.
https://t.co/zsc2eBVI4e Tons of great preclinical work on TIE2 MOA showing clear correlation to SC integrity, adult-onset glaucoma, and disease-modifying effects. See mosaic if interested
can you share the preclinical work you describe along with the papers?
— James Brandt (@jmsbrandt) November 20, 2020
What do KOL's think of the new MOA: Special session held at ARVO 2019 to discuss Tie2 for Glaucoma. $ARPO then completed a closely watched P1b with a topical formulation. Now, a P2b trial in 195 pts enrolled within 3 mos, a month ahead of schedule, in the middle of a pandemic.
SOC is PG (-7 mm Hg IOP) +/- adjunct (-1 to -1.5 mm delta). Best efficacy adjunct is Rocklatan (-1.5), but AE profile: hyperemia (60 vs 15%), pruritus (8 vs 2%) site pain (20 vs 7%) vs PG , + other AEās not seen with PG: 10% conjunctival hemorrhage, 15% verticillata. Almost DOA
But, sells $80 to $100M/yr US (same as $ARPO MC ha!). Every 0.3 mm reduction critical towards delaying vision loss. Rocklatan MOA was projected to make it a $1B drug, until AE profile (& payor delays) killed launch. $ARPO thesis: Raz efficacy >/= Rocklatan, without AE baggage.
Ok here is the extended thread on $XL I promised.
It is pretty straight forward.
For those that are new to stocks / options (because of the influx of interest due to $GME, $AMC, $SLV, etc), here are some terms you should google:
-Short Interest
-Call option
-Open Interest
/1
XL Fleet short interest increased from 50% to 72% in the latest reporting (came out Friday)
That alone piqued my curiosity in the company so I took a position in some Feb calls (in my robinhood account) and will be adding more in my TD account this coming week.
/2
Several days ago, Biden announced that he would be replacing the entire govt. fleet with electric vehicles
https://t.co/DNNMOwq6dv
$WKHS got a massive pump on this news but that was about it.
Who are the other likely candidates? $GOEV and $XL
Why is $XL one of the top candidates?
-Partnerships with Coke and Pepsi
-Board of Director members have strong ties with UPS and FedEx
-Management team is very connected in govt. associations for clean energy in wind, solar, and EV
- $XL is focused on transforming existing FLEETS
All of this can be found on their
It is pretty straight forward.
For those that are new to stocks / options (because of the influx of interest due to $GME, $AMC, $SLV, etc), here are some terms you should google:
-Short Interest
-Call option
-Open Interest
/1
XL Fleet short interest increased from 50% to 72% in the latest reporting (came out Friday)
That alone piqued my curiosity in the company so I took a position in some Feb calls (in my robinhood account) and will be adding more in my TD account this coming week.
/2
Several days ago, Biden announced that he would be replacing the entire govt. fleet with electric vehicles
https://t.co/DNNMOwq6dv
$WKHS got a massive pump on this news but that was about it.
Who are the other likely candidates? $GOEV and $XL
Why is $XL one of the top candidates?
-Partnerships with Coke and Pepsi
-Board of Director members have strong ties with UPS and FedEx
-Management team is very connected in govt. associations for clean energy in wind, solar, and EV
- $XL is focused on transforming existing FLEETS
All of this can be found on their
I have started a position in $SSPK.
-
SPAC - $SSPK Silver Spike Acquisition Comp
They are merging with WM Holdings, Inc who owns Weedmaps. Founded in 2008. Lead by CEO Chris Beals. Former life-sciences attorney (important - will come in later).
Basic Description:
The business is a two-sided marketplace which serves customers and sellers of marijuana products.
Who are they?
On the consumer side, https://t.co/sHZKPFCY7I which is a marketplace for standardized marijuana products.
Weed Maps is the worldās largest base of cannabis users with over 10M MAUs, 90% of which are cannabis users, and a stunning 70% are DAILY users.
A key part of the marketplace is the differentiation between alcohol/tobacco and cannabis. Cannabis is *not* a standardized product so Weedmaps compiles millions of data points from strain traits, user feedback, effects, etc., to suggest the best products for the user.
Weedmaps is operating at a 1.5B GMV run rate. With cannabis illegal on the Federal level, they do not currently take a percentage of this GMW but stated that they plan to with Federal legalization.
-
SPAC - $SSPK Silver Spike Acquisition Comp
They are merging with WM Holdings, Inc who owns Weedmaps. Founded in 2008. Lead by CEO Chris Beals. Former life-sciences attorney (important - will come in later).
Started a new position today. Will be working on my first in-depth write-up.
— Plant (@plantmath1) December 16, 2020
Basic Description:
The business is a two-sided marketplace which serves customers and sellers of marijuana products.
Who are they?
On the consumer side, https://t.co/sHZKPFCY7I which is a marketplace for standardized marijuana products.
Weed Maps is the worldās largest base of cannabis users with over 10M MAUs, 90% of which are cannabis users, and a stunning 70% are DAILY users.
A key part of the marketplace is the differentiation between alcohol/tobacco and cannabis. Cannabis is *not* a standardized product so Weedmaps compiles millions of data points from strain traits, user feedback, effects, etc., to suggest the best products for the user.
Weedmaps is operating at a 1.5B GMV run rate. With cannabis illegal on the Federal level, they do not currently take a percentage of this GMW but stated that they plan to with Federal legalization.
Quick thread on #NIODay from this weekend, the effect it is having on $TSLA, $BYDDF, $QS, $LAZR, $NVDA, CATL, and what is to come.
The NIO ET7 boasts 621mi range (150kWh battery) for $70k-$80k & Level 3 autonomy. This prices right in-between Model 3 SR+ & base Model S.
2/ $TSLA is down -6% today, largely on this news. Not surprising, but TSLA bulls aren't flinching from this. NIO ET7 isn't really expected to hit the roads until late next yearāenough time for Tesla to refresh S/X & boost pack size, TSLA bulls think.
$NIO is up 8.5% today.
3/ BYD (1211 HK) was up 6.7% in China on Monday partially on the news of its surprise unveiling this morning of 3 new "super hybrid" models (PHEV): Qin PLUS DM-i, Song PLUS DM-i, & Tang DM-i.
$BYDDF is up 3.5% today
4/ BYD is also benefiting from #NIODay, as investors are excited about NIO ET7 specs, but it is still at least a year out. More investors are discovering BYD & how far ahead it is TODAY. BYD Han in particular already looks similar to NIO ET7...
$BYDDF $BYDDY
5/ ...and you can buy a Han today for only $32k. Lots of investor attention has been brought to BYD Blade battery, as well.
More on BYD here: https://t.co/rbiX4sZtdN
https://t.co/SYLpij5dTe
$BYDDF $BYDDY
The NIO ET7 boasts 621mi range (150kWh battery) for $70k-$80k & Level 3 autonomy. This prices right in-between Model 3 SR+ & base Model S.
2/ $TSLA is down -6% today, largely on this news. Not surprising, but TSLA bulls aren't flinching from this. NIO ET7 isn't really expected to hit the roads until late next yearāenough time for Tesla to refresh S/X & boost pack size, TSLA bulls think.
$NIO is up 8.5% today.
3/ BYD (1211 HK) was up 6.7% in China on Monday partially on the news of its surprise unveiling this morning of 3 new "super hybrid" models (PHEV): Qin PLUS DM-i, Song PLUS DM-i, & Tang DM-i.
$BYDDF is up 3.5% today
4/ BYD is also benefiting from #NIODay, as investors are excited about NIO ET7 specs, but it is still at least a year out. More investors are discovering BYD & how far ahead it is TODAY. BYD Han in particular already looks similar to NIO ET7...
$BYDDF $BYDDY
5/ ...and you can buy a Han today for only $32k. Lots of investor attention has been brought to BYD Blade battery, as well.
More on BYD here: https://t.co/rbiX4sZtdN
https://t.co/SYLpij5dTe
$BYDDF $BYDDY
The guy I used to work with (Iāll call him āQā) who shorted $TSLA at $600 in Dec called me today:
Q: Why is $TSLA up 6% on no news?
GB: Because it was down 8% yesterday on no news - unless you call a 10 bp rise in treasury yields and $BTC collapsing news. You still short?
2/ Q: Of course Iām still short. Itās up another 30% since we talked two weeks ago. Itās all moā.
GB: $TSLA MIC Y has a 4 mo wait. Itās entering India. Analysts are playing leapfrog raising PTs. Active mgrs have to own it or get fired. Itās cheap at 80x 2022 EPS vs 55% growth.
3/ Q: Your earnings estimates are like twice consensus.
GB: The Streetās been wrong on $TSLA forever. Why do you listen to them? You really shouldnāt be short going into Bidenās inaugural speech and the FYā21 volume guide at the end of Jan. Youāre going to get run over.
4/ Q: Whatever.
GB: Did you rent a Tesla for a week like I told you?
Q: No. You know I donāt drive.
GB: Did you build a $TSLA 5-yr volume, earnings, cash flow model?
Q: No. No one can forecast out 5 years.
GB: Did you talk to any Audi or BMW dealers? Or Tesla owners?
5/ Q: I donāt have time for that.
GB: Q, you havenāt done any real research. $TSLA ās up 40% since you shorted it. Maybe you should figure out why it keeps going up.
Q: It keeps going up because people like you are pumping it.
GB: Youāre giving people like me too much credit.
Q: Why is $TSLA up 6% on no news?
GB: Because it was down 8% yesterday on no news - unless you call a 10 bp rise in treasury yields and $BTC collapsing news. You still short?
I had a two-day email exchange with a guy I used to work with who now runs a $600M hedge fund and shorted $TSLA at $600. He\u2019s now kicking himself as $TSLA approaches $700. Amazingly:
— Gary Black (@garyblack00) December 28, 2020
1/ He\u2019s a value investor who doesn\u2019t own growth stocks, but thinks he can short growth stocks.
2/ Q: Of course Iām still short. Itās up another 30% since we talked two weeks ago. Itās all moā.
GB: $TSLA MIC Y has a 4 mo wait. Itās entering India. Analysts are playing leapfrog raising PTs. Active mgrs have to own it or get fired. Itās cheap at 80x 2022 EPS vs 55% growth.
3/ Q: Your earnings estimates are like twice consensus.
GB: The Streetās been wrong on $TSLA forever. Why do you listen to them? You really shouldnāt be short going into Bidenās inaugural speech and the FYā21 volume guide at the end of Jan. Youāre going to get run over.
4/ Q: Whatever.
GB: Did you rent a Tesla for a week like I told you?
Q: No. You know I donāt drive.
GB: Did you build a $TSLA 5-yr volume, earnings, cash flow model?
Q: No. No one can forecast out 5 years.
GB: Did you talk to any Audi or BMW dealers? Or Tesla owners?
5/ Q: I donāt have time for that.
GB: Q, you havenāt done any real research. $TSLA ās up 40% since you shorted it. Maybe you should figure out why it keeps going up.
Q: It keeps going up because people like you are pumping it.
GB: Youāre giving people like me too much credit.
Seeing a lot of popular names down big today, so letās have a little chat.
What do you do when your hot stock is falling fast?
š„ (a thread)
Check your goals.
When do you need this money?
Now? In a few days? In a few years?
If you have time to wait, then it could make sense to hold on for now.
Remember your why.
Stocks rise and fall. Itās the nature of the market, and swings are the price of investing (h/t @morganhousel).
Just think about Apple. Amazing rally over the past few decadesā¦with a lot of big
Back to the why. If your why behind buying this stock hasnāt changed, then it might be best to wait this drop out.
What do you do when your hot stock is falling fast?
š„ (a thread)
Check your goals.
When do you need this money?
Now? In a few days? In a few years?
If you have time to wait, then it could make sense to hold on for now.
Remember your why.
Stocks rise and fall. Itās the nature of the market, and swings are the price of investing (h/t @morganhousel).
Just think about Apple. Amazing rally over the past few decadesā¦with a lot of big
What they tell you:
— Callie Cox (@callieabost) September 24, 2020
If you invested $100 in Apple's IPO and and held shares until today, that investment would be worth about $100,000.
What they don't tell you:
If you invested $100 in Apple's IPO and held shares until today, you would've endured 23 declines of 20% or more.
Back to the why. If your why behind buying this stock hasnāt changed, then it might be best to wait this drop out.
1/ n As promised, a quick thread. Combination of my (non-PhD / layman's) dive into learning about Monoclonal Antibodies and how it's helped me uncover a few fun / interesting group of companies: $SDGR $ABCL $TWST $IPA (new QQQ uplist -formerly $IPATD) and most recently $LGND
Ok - first, a *quick* history lesson - in the last ~3 months, I have been increasingly obsessed w/ learning about monoclonal antibodies. It started as a simple pattern recognition that a lot of the biotechs I was investing in were in this space - $HGEN $PRVB $MGNX $ONCT etc.
Not to mention, all of these new COVID therapeutics ( $LLY $REGN ) were antibody based - what the heck exactly are these things? I found myself watching basic videos - like this simple 3 minute cartoon summary...
.. to this podcast on the history of monoclonal antibodies, like this Nature podcast: https://t.co/iXcq56RR5l And a bunch of more academic / scientific white papers and articles that are far too dry to share here
Probably a good time to add that I barely made it past high school biology - my academic and professional background is all based around finance / math / SaaS - so as much as I'm interested in biotechnology, it's all self-taught and I needed to start with the basics
Ok - first, a *quick* history lesson - in the last ~3 months, I have been increasingly obsessed w/ learning about monoclonal antibodies. It started as a simple pattern recognition that a lot of the biotechs I was investing in were in this space - $HGEN $PRVB $MGNX $ONCT etc.
Not to mention, all of these new COVID therapeutics ( $LLY $REGN ) were antibody based - what the heck exactly are these things? I found myself watching basic videos - like this simple 3 minute cartoon summary...
.. to this podcast on the history of monoclonal antibodies, like this Nature podcast: https://t.co/iXcq56RR5l And a bunch of more academic / scientific white papers and articles that are far too dry to share here
Probably a good time to add that I barely made it past high school biology - my academic and professional background is all based around finance / math / SaaS - so as much as I'm interested in biotechnology, it's all self-taught and I needed to start with the basics